Nice $7,027 start to the week on my end applying high probability trade ideas…
Today, financial professionals at Morgan Stanley are analyzing a stock which I just made 196% on last week as it was my #1 trade idea on May 6, 2020.
Today, I’m interested in moving the other direction on it, and I suspect some at Morgan Stanley are as well!
| Ticker Code | Ticker Name | Ticker Industry | Price Change | Average Volume (50)* |
| ACB | Aurora Cannabis Inc | Drug Manufacturers – Specialty & Generic | 30.37% | 15,019,194 |
| KTOV | KITOV PHARMA LT/S ADR | Biotechnology | 44.64% | 21,231,681 |
| SPOT | Spotify Technology SA | Internet Content & Information | 36.42% | 1,744,952 |
| INO | Inovio Pharmaceuticals Inc | Biotechnology | 48.55% | 40,677,485 |
| NVAX | Novavax, Inc. | Biotechnology | 71.81% | 11,100,926 |
| WBA | Walgreens Boots Alliance Inc | Pharmaceutical Retailers | -8.52% | 6,707,004 |
| SNDX | Syndax Pharmaceuticals Inc | Biotechnology | 30.08% | 1,401,338 |
| CHK | Chesapeake Energy Corporation | Oil & Gas E&P | -149.21% | 3,014,128 |
| BABA | Alibaba Group Holding Ltd – ADR | Internet Retail | 3.59% | 20,648,485 |
| DSS | Document Security Systems, Inc. | Specialty Business Services | 23.75% | 275,195 |
| PENN | Penn National Gaming, Inc | Resorts & Casinos | 56.81% | 14,208,069 |
| IQ | IQIYI Inc | Internet Content & Information | -12.16% | 7,832,697 |
| MRNA | Moderna Inc | Biotechnology | 48.10% | 24,051,944 |
| GE | General Electric Company | Specialty Industrial Machinery | -16.76% | 126,460,843 |
| TRIL | Trillium Therapeutics Inc | Biotechnology | 35.97% | 2,306,206 |
| CRWD | Crowdstrike Holdings Inc | Software – Application | 29.83% | 4,205,427 |
| BYND | Beyond Meat Inc | Packaged Foods | 49.88% | 11,274,089 |
| HGSH | CAHS China HGS Real Estate, Inc. Common Stock | Real Estate – Development | 20.00% | 131,820 |
| LK | Luckin Coffee Inc – ADR | Restaurants | -1176.53% | 10,989,912 |
| MRVL | Marvell Technology Group Ltd. | Semiconductors | 25.56% | 8,884,418 |
America’s #1 Premarket and Day Trader
Only minutes after Benchmark upgraded their rating on Inovio Pharmaceuticals (NYSE: INO), a shareholder rights law firm announced the initiation of an investigation of the officers and directors of the company.
Something might have seemed a little fishy!
It is rumored that INO may have recently breached fiduciary duties and violated Securities and Exchange Commission Acts.
On top of that, in recent days INO has been accused of falsifying their favorable COVID-19 vaccine claims made last week.
And as mentioned last week, I was interested in a short-term upside move on their COVID-19 vaccine catalyst, but also stated that I didn’t like the company’s management and may look to short it back down later.
I think that time has now come as I am bearish on INO in the long-term and retain my cynicism of the company’s officers and directors (who are now under investigation).
A mistake many new traders make when attempting to short stocks down after they make significant moves up is either chasing them or not having a trade plan.
I’ve been planning this possible short opportunity for about a week, and today I believe it could come together, allowing me to initiate a starter position.
$15/share has been tough resistance for INO to trade above for more than an hour or two at a time so far in 2020. Therefore, should INO trade around $15/share, that’s exactly when I’ll initiate a bearish position.
If this setup comes together today, I suspect I won’t be the only one placing a bearish bet on INO itself, and you bet I’ll be watching Wall Street’s biggest players trading activity on INO today as well!
Yours for TrackStar trading,
Davis Martin
America’s #1 Premarket and Day Trader
Disclaimer: This is not investment advice. This article is for information purposes only and opinion-based on financial advisor data across a selection of websites. Investors should be cautious about any and all investments and are advised to conduct their own due diligence prior to making any investment decisions.